Hematology — Medicare Part B billing by state
6 physician groups whose primary specialty is Hematology billed $0.01B to Medicare fee-for-service in 2024.
Calendar year 2024 · Medicare fee-for-service Part B
| State | Groups | Services | Beneficiary-episodes | Medicare payments | Standardized payments ↓ | Payments / group | Services / group |
|---|---|---|---|---|---|---|---|
| California | 3 | 542,114 | 14,133 | $8,718,952 | $8,508,105 | $2,906,317 | 180,705 |
| Pennsylvania | 1 | 149,832 | 8,051 | $3,230,676 | $3,203,226 | $3,230,676 | 149,832 |
| New Jersey | 1 | 67,903 | 2,289 | $479,382 | $446,507 | $479,382 | 67,903 |
| Texas | 1 | 15 | 15 | $1,188 | $1,161 | $1,188 | 15 |
Need this specialty's market in one document?
Notify me at launchEach group carries one specialty label — the specialty most common among its clinicians in CMS's Doctors and Clinicians register — so every figure on this page counts groups, not individual clinicians. An organization's entire Medicare billing is credited to that one label, so a specialty's totals reflect how organizations are labeled, not the specialty of each service; large multi-specialty organizations — where no single specialty is a majority of the clinicians — account for much of the volume shown under many specialties. Totals include only volume that can be credited to a single group; clinicians registered with more than one group are left out of group totals and shown as “—” elsewhere on Nevvi. Clinicians not registered with any group, and groups without a specialty label, are also not included. A group is counted in every state its clinicians bill Medicare from, so state figures overlap and never sum to the national figure.
All figures are Medicare fee-for-service Part B only; Medicare Advantage claims are not included. Cross-state comparisons use standardized payments, which remove regional differences in what Medicare pays; services without a standardized amount — mainly Part B drugs — are not in that column, and the Medicare payments column shows what Medicare actually paid. Beneficiary counts are beneficiary-episodes: one person treated in more than one setting or state is counted in each.
Top codes by Medicare payments CY2024
| Code | Services | Medicare payments ↓ | Largest state markets |
|---|---|---|---|
| J0897 · Injection, denosumab, 1 mg | 114,960 | $2,343,341 | CAPANJTX |
| J9271 · Injection, pembrolizumab, 1 mg | 27,200 | $1,216,412 | CAPANJTX |
| J1569 · Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 27,310 | $967,083 | CAPANJTX |
| 99214 · Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | 8,902 | $859,338 | CAPANJTX |
| 78815 · Nuclear medicine study from skull base to mid-thigh with ct scan | 628 | $858,637 | CAPANJTX |
| J9299 · Injection, nivolumab, 1 mg | 44,640 | $838,795 | CAPANJTX |
| 96413 · Administration of chemotherapy into vein, 1 hour or less | 5,336 | $575,628 | CAPANJTX |
| J1449 · Injection, eflapegrastim-xnst, 0.1 mg | 23,364 | $475,527 | CAPANJTX |
| J9352 · Injection, trabectedin, 0.1 mg | 1,638 | $448,106 | CAPANJTX |
| J2356 · Injection, tezepelumab-ekko, 1 mg | 27,930 | $397,498 | CAPANJTX |
| Q0138 · Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) top by services | 148,410 | $40,288 | CAPANJTX |
| J1439 · Injection, ferric carboxymaltose, 1 mg top by services | 46,500 | $40,269 | CAPANJTX |
| J9263 · Injection, oxaliplatin, 0.5 mg top by services | 70,480 | $3,772 | CAPANJTX |
| J1100 · Injection, dexamethasone sodium phosphate, 1 mg top by services | 33,860 | $3,023 | CAPANJTX |
Every code above is searchable free at full depth. Ranking organizations across several codes at once — one combined market view — is part of a Nevvi subscription.
Notify me at launch